Publications - Louis Letendre, M.D.

Back to Research Profile

1. Mauermann ML, Angius D, Spinner RJ, Letendre LJ, Amrami KK, Dyck PJ. Isolated granulocytic sarcoma presenting as a brachial plexopathy. J Peripher Nerv Syst 2008 Jun; 13(2):153-156.
   View PubMed
2. Mauermann ML, Angius D, Spinner RJ, Letendre L, Amrami KK, Dyck PJB. Isolated granulocytic sarcoma presenting as a brachial plexopathy. J Peripher Nerv Syst 2008 Jun; 13(2):153-6.
   View PubMed
3. Elliott MA, Litzow MR, Letendre L, Wolf RC, Hanson CA, Tefferi A, Tallman MS. Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survival. Blood 2007 Dec 15; 110(13):4172-4 Epub 2007 Oct 1.
   View PubMed
4. Elliott MA, Litzow MR, Letendre LL, Wolf RC, Hanson CA, Tefferi A, Tallman MS. Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survival. Blood 2007 Dec 15; 110(13):4172-4. Epub 2007 Oct 01.
   View PubMed
5. Elliott MA, Tefferi A, Hogan WJ, Letendre L, Gastineau DA, Ansell SM, Dispenzieri A, Gertz MA, Hayman SR, Inwards DJ, Lacy MQ, Micallef IN, Porrata LF, Litzow MR. Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia. Bone Marrow Transplant 2006 Jun; 37(11):1003-8.
   View PubMed
6. Behl D, Porrata LF, Markovic SN, Letendre L, Pruthi RK, Hook CC, Tefferi A, Elliot MA, Kaufmann SH, Mesa RA, Litzow MR. Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia. Leukemia 2006 Jan; 20(1):29-34.
   View PubMed
7. Behl D, Porrata LF, Markovic SN, Letendre L, Pruthi RK, Hook CC, Tefferi A, Elliott MA, Kaufmann SH, Mesa RA, Litzow MR. Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia. Leukemia 2006 Jan; 20(1):29-34.
   View PubMed
8. Litzow MR, Dietz AB, Bulur PA, Butler GW, Gastineau DA, Hoering A, Fink SR, Letendre L, Padley DJ, Paternoster SF, Tefferi A, Vuk-Pavlovic S. Testing the safety of clinical-grade mature autologous myeloid DC in a phase I clinical immunotherapy trial of CML. Cytotherapy 2006; 8(3):290-8.
   View PubMed
9. Kaufmann SH, Karp JE, Letendre L, Kottke TJ, Safgren S, Greer J, Gojo I, Atherton P, Svingen PA, Loegering DA, Litzow MR, Sloan JA, Reid JM, Ames MM, Adjei AA, Erlichman C. Phase I and pharmacologic study of infusional topotecan and carboplatin in relapsed and refractory acute leukemia. Clin Center Res 2005 Sep 15; 11(18):6641-9.
   View PubMed
10. Chen YC, Chou JM, Letendre L, Li CY. Clinical importance of bone marrow monocytic nodules in patients with myelodysplasia: Retrospective analysis of 21 cases. Am J Hematol 2005 Aug; 79(4):329-31.
    View PubMed
11. Gore SD, Smith BD, Gojo I, Grever M, Kaufmann SH, Letendre L, Leonard DGB, Marcucci G, Miller CB, Morris L, Piantadosi S, Prior T, Stock W, Karp JE. Durable molecular remissions with a single cycle of timed sequential consolidation chemotherapy in acute promyelocytic leukemia. Am J Hematol 2005 Jun; 79(2):119-27.
    View PubMed
12. Elliott MA, Wolf RC, Hook CC, Pruthi RK, Heit JA, Letendre LL, Tefferi A, Kaufmann SH, Mesa RA, Litzow MR. Thromboembolism in adults with acute lymphoblastic leukemia during induction with L-asparaginase-containing multi-agent regimens: Incidence, risk factors, and possible role of antithrombin. Leukemia & Lymphoma 2004 Aug; 45(8):1545-9.
    View PubMed
13. Greenberg PL, Lee SJ, Advani R, Tallman MS, Sikic BI, Letendre L, Dugan K, Lum B, Chin DL, Dewald G, Paietta E, Bennett JM, Rowe JM. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: A phase III trial (E2995). J Clin Oncol 2004 Mar 15; 22(6):1078-86.
    View PubMed
14. Chen YC, Chou JM, Ketterling RP, Letendre L, Li CY. Histologic and immunohistochemical study of bone marrow monocytic nodules in 21 cases with myelodysplasia. Am J Clin Pathol 2003 Dec; 120(6):874-81.
    View PubMed
15. Litzow MR, Repoussis PD, Schroeder G, Schembri-Wismayer D, Batts KP, Anderson PM, Arndt CAS, Chen MG, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Tefferi A, Noel P, Solberg LA, Letendre L, Hoagland HC. Veno-occlusive disease of the liver after blood and marrow transplantation: Analysis of pre- and post-transplant risk factors associated with severity and results of therapy with tissue plasminogen activator. Leuk Lymphoma 2002 Nov; 43(11):2099-107.
    View PubMed
16. Hogan WJ, Letendre L, Litzow MR, Tefferi A, Hoagland HC, Pruthi RK, Kaufmann SH. Neutropenic colitis after treatment of acute myelogenous leukemia with idarubicin and cytosine arabinoside. Mayo Clin Proc 2002 Aug; 77(8):760-2.
    View PubMed
17. Porrata LF, Litzow MR, Tefferi A, Letendre L, Kumar S, Geyer SM, Markovic SN. Early lymphocyte recovery is a predictive factor for prolonged survival after autologous hematopoietic stem cell transplantation for acute myelogenous leukemia. Leukemia 2002 Jul; 16(7):1311-8.
    View PubMed
18. Elliott MA, Letendre L, Hanson CA, Tefferi A, Dewald GW. The prognostic significance of trisomy 8 in patients with acute myeloid leukemia. Leukemia & Lymphoma 2002 Mar; 43(3):583-6.
    View PubMed
19. Tack DK, Letendre L, Kamath PS, Tefferi A. Development of hepatic veno-occlusive disease after Mylotarg infusion for relapsed acute myeloid leukemia. Bone Marrow Transplant 2001 Nov; 28(9):895-7.
    View PubMed
20. Steensma DP, Hanson CA, Letendre L, Tefferi A. Myelodysplasia with fibrosis: a distinct entity? Leuk Res 2001 Oct; 25(10):829-838.
    View PubMed
21. Greenlund LJS, Letendre L, Tefferi A. Acute leukemia during pregnancy: a single institutional experience with 17 cases. Leuk Lymphoma 2001 May; 41(5-6):571-577.
    View PubMed
22. Tefferi A, Elliott MA, Steensma DP, Hook CC, Dispenzieria A, Hanson CA, Schroeder G, Letendre L. Amifostine alone and in combination with erythropoietin for the treatment of favorable myelodysplastic syndrome. Leuk Res 2001 Feb; 25(2):183-5.
    View PubMed
23. Robles C, Kim KM, Oken MM, Bennett JM, Letendre L, Wiernik PH, O'Connell MJ, Cassileth PA. Low-dose cytarabine maintenance therapy vs observation after remission induction in advanced acute myeloid leukemia: an Eastern Cooperative Oncology Group Trial (E5483). Leukemia 2000 Aug; 14(8):1349-53.
    View PubMed
24. van Der Vliet HJ, Roberson AE, Hogan MC, Morales CE, Crader SC, Letendre L, Pruthi RK. All-trans-retinoic acid-induced myositis: a description of two patients. Am J Hematol 2000 Feb; 63(2):94-8.
    View PubMed
25. Letendre L, Noel P, White WL, Tefferi A, Litzow MR, Li CY, Schroeder G. Treatment of unfavorable myelodysplastic syndrome with all-trans-retinoic acid and subcutaneous Ara C. Leuk Res 1999 Sep; 23(9):811-5.
    View PubMed
26. Elliott MA, Letendre L, Li CY, Hoyer JD, Hammack JE. Chronic lymphocytic leukaemia with symptomatic diffuse central nervous system infiltration responding to therapy with systemic fludarabine. Br J Haematol 1999 Mar; 104(4):689-94.
    View PubMed
27. Mongkonsritragoon W, Letendre L, Li CY. Multiple lymphoid nodules in bone marrow have the same clonality as underlying myelodysplastic syndrome recognized with fluorescent in situ hybridization technique. Am J Hematol 1998 Nov; 59(3):252-7.
    View PubMed
28. Mongkonsritragoon W, Letendre L, Qian J, Li CY. Nodular lesions of monocytic component in myelodysplastic syndrome. Am J Clin Pathol 1998 Aug; 110(2):154-62.
    View PubMed
29. Letendre L, Noel P, Litzow MR, Hoagland HC, Tefferi A. Treatment of acute myelogenous leukemia in the older patient with attenuated high-dose ara-C. Am J Clin Oncol 1998 Apr; 21(2):142-4.
    View PubMed
30. Letendre L, Moore SB. Successful pregnancy after conditioning with cyclophosphamide and fractionated total body irradiation. Medical & Pediatric Oncology 1997 Feb; 28(2):147-8.
    View PubMed
31. Kaufmann SH, Gore SD, Letendre L, Svingen PA, Kottke T, Buckwalter CA, Jones RJ, Grochow LB, Burke PJ, Donehower RC, Rowinsky EK. Factors affecting topotecan sensitivity in human leukemia samples. Ann N Y Acad Sci 1996 Dec 13; (803):128-42.
32. Letendre L, Noel P, Tefferi A, Solberg LA Jr, Gastineau DA, Hoagland HC. Continuous infusion etoposide/carboplatin for treatment of refractory acute leukemia. Am J Clin Oncol 1995 Oct; 18(5):382-4.
    View PubMed
33. Witzig TE, Letendre L, Gerstner J, Schroeder G, Mailliard JA, Colon-Otero G, Marschke RF, Windschitl HE. Evaluation of a somatostatin analog in the treatment of lymphoproliferative disorders: results of a phase II North Central Cancer Treatment Group trial. J Clin Oncol 1995 Aug; 13(8):2012-5.
    View PubMed
34. Letendre L, Levitt R, Pierre RV, Schroeder G, Krook JA, Mailliard JE, Morton RF, Tschetter LK. Myelodysplastic syndrome treatment with danazol and cis-retinoic acid. Am J Hematol 1995 Apr; 48(4):233-6.
    View PubMed
35. Gertz MA, Pineda AA, Chen MG, Letendre L, Greipp PR, Solberg LA Jr, Witzig TE, Garton JP, Inwards DJ, Litzow MR, Tefferi A, Kyle R, Noel P. Refractory and relapsing multiple myeloma treated by blood stem cell transplantation. Am J Med Sci 1995 Mar;309(3):152-61.
    View PubMed
36. Letendre L, Hoagland HC, Moore SB, Chen MG, Gastineau DA, Gertz MA, Habermann TM, Litzow MR, Noel P, Solberg LA Jr, Tefferi A. Mayo Clinic experience with allogeneic and syngeneic bone marrow transplantation, 1982 through 1990. Mayo Clin Proc 1992 Feb; 67(2):109-16.
    View PubMed
37. Afessa B, Tefferi A, Hoagland HC, Letendre L, Peters SG. Outcome of recipients of bone marrow transplants who require intensive-care unit support. Mayo Clin Proc 1992 Feb; 67(2):117-22.
    View PubMed
38. Letendre L, Hoagland HC, Gertz MA. Hemorrhagic cystitis complicating bone marrow transplantation. Mayo Clin Proc 1992 Feb; 67(2):128-30.
    View PubMed
39. Graham DL, Tefferi A, Letendre L, Gastineau DA, Hoagland HC, Noel P. Cytogenetic and molecular detection of residual leukemic cells after allogeneic bone marrow transplantation in chronic granulocytic leukemia. Mayo Clin Proc 1992 Feb; 67(2):123-7.
    View PubMed
40. Brecher ME, Moore SB, Letendre L. Posttransfusion purpura: the therapeutic value of p1-a1-negative platelets. Transfusion (Paris) 1990 Jun; 30:433-435.
    View PubMed
41. Lust JA, Letendre L, Thibodeau SN. Marrow hypoplasia associated with a monoclonal CD8 large granular lymphocyte proliferation: reversal with cyclophosphamide and prednisone. Am J Med 1989 Aug; 87(2):214-7.
    View PubMed
42. Letendre L. Treatment of lymphomatoid granulomatosis: old and new perspectives. Semin Respir Med 1989 Apr; 10:178-181.
43. Letendre L, Niedringhaus RD, Therneau TM, Gastineau DA, Goldberg RM, Gerstner JB, Mailliard JA, Gundlach WJ, Kardinal CG, Pierre RV. Treatment of acute nonlymphocytic leukemia in the elderly with intermediate high-dose cytosine arabinoside. Medical & Pediatric Oncology 1989; 17(2):79-82.
    View PubMed
44. Diez-Martin JL, Habermann TM, Gastineau DA, Solberg LA Jr, Letendre L. Nonbacterial thrombotic endocarditis in autologous bone marrow transplantation. Am J Med 1988 Nov; 85(5):742-4.
    View PubMed
45. Kriegshauser JS, Charboneau JW, Letendre L. Hepatic venocclusive disease after bone-marrow transplantation: diagnosis with duplex sonography. AJR Am J Roentgenol 1988 Feb; 150(2):289-90.
    View PubMed
46. Morrison-DeLap SJ, Kuffel DG, Dewald GW, Letendre L. Unbalanced 1;7 translocation and therapy-induced hematologic disorders: a possible relationship. Am J Hematol 1986 Jan; 21(1):39-47.
    View PubMed
47. Mailliard JA, Letendre L, Dalton RJ, Levitt R, Gerstner JB, Therneau TM, Pierre RV. Phase I-II trial of VP-16 in the treatment of acute nonlymphocytic leukemia and blast crisis of chronic granulocytic leukemia. Med Pediatr Oncol 1986; 14(6):306-9.
    View PubMed
48. Johnson DD, Dewald GW, Pierre RV, Letendre L, Silverstein MN. Deletions of chromosome 13 in malignant hematologic disorders. Cancer Genetics & Cytogenetics 1985 Nov; 18(3):235-41.
    View PubMed
49. Moore SB, Motschman TL, Dewald GW, Letendre L, Smithson WA, Hoagland HC. A case of unusually early but temporary humoral immune reconstitution after bone marrow transplantation. Transplantation 1985 Jun; 39(6):675-7.
    View PubMed
50. Witzig TE, Ducatman BS, Wick MR, Letendre L, Moore SB, Ilstrup DM, Taswell HF. Platelet transfusion therapy in acute leukemia: lack of effect of splenomegaly on transfusion requirements and risk of hemorrhage. Am J Hematol 1985 Apr; 18(4):345-50.
    View PubMed
51. Letendre L, Hinemann V, Hoagland HC, Kovach JS. Phase I study of VP-16 (etoposide) and amsacrine (AMSA) in the treatment of refractory acute leukemia. Medical & Pediatric Oncology 1985; 13(4):232-4.
    View PubMed
52. Letendre L, Ludwig J, Perrault J, Smithson WA, Kovach JS. Hepatocellular toxicity during the treatment of refractory acute leukemia with indicine N-oxide. Cancer 1984 Oct 1; 54(7):1256-9.
    View PubMed
53. Vaickus L, Letendre L. Pericarditis induced by high-dose cytarabine therapy. Arch Intern Med 1984 Sep; 144(9):1868-9.
    View PubMed
54. Letendre L, Kiely JM, Hoagland HC. Reinduction chemotherapy for acute nonlymphocytic leukemia. Mayo Clin Proc 1984 Sep; 59(9):618-21.
    View PubMed
55. Letendre L, Kyle RA. Monoclonal cryoglobulinemia with high thermal insolubility. Mayo Clin Proc 1982 Oct; 57(10):629-33.
    View PubMed
56. Letendre L, Colgan JP, Hineman VL, Hoagland HC. Treatment of adult acute lymphocytic leukemia. Mayo Clin Proc 1982 Jul; 57(7):426-30.
    View PubMed
57. Letendre L, Banks PM, Reese DF, Miller RH, Scanlon PW, Kiely JM. Primary lymphoma of the central nervous system. Cancer 1982 Mar 1; 49(5):939-43.
    View PubMed
58. Hoagland HC, Letendre L. Bone marrow transplantation. Mayo Clin Proc 1981 Mar; 56:204.
59. Letendre L, Smithson WA, Gilchrist GS, Burgert EO Jr, Hoagland CH, Ames MM, Powis G, Kovach JS. Activity of indicine N-oxide in refractory acute leukemia. Cancer 1981 Feb 1; 47(3):437-41.
    View PubMed
60. Edmonson JH, Frytak S, Letendre L, Kvols LK, Eagan RT. Phase II evaluation of dianhydrogalactitol in advanced head and neck carcinomas. Cancer Treat Rep 1979 Nov-Dec; 63(11-12):2081-3.
    View PubMed